BioLife Solutions, Inc. Proceeds from Sale of Debt Securities, Available-for-sale
BioLife Solutions, Inc. (BLFS) reported Proceeds from Sale of Debt Securities, Available-for-sale of $4.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- BioLife Solutions, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-06-30 was $2.36M, a 99.58% increase year-over-year.
- BioLife Solutions, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-03-31 was $2.33M, a 306.81% increase year-over-year.
- BioLife Solutions, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-12-31 was $3.24M, a 256.22% increase year-over-year.
- BioLife Solutions, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-09-30 was $1.84M, a 124.18% increase year-over-year.
- BioLife Solutions, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2025 was $6.83M, a 94.12% increase from fiscal 2024.
- BioLife Solutions, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2024 was $3.52M, a 1.41% increase from fiscal 2023.
- BioLife Solutions, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2023 was $3.47M, a 725.95% increase from fiscal 2022.
- BioLife Solutions, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2022 was $420.00K.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.69M 10-Q · filed 2026-08-06 | $7.93M derived: sum of 3 quarters · filed 2026-08-06 | $9.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.33M 10-Q · filed 2026-05-07 | $5.57M derived: sum of 2 quarters · filed 2026-05-07 | $7.41M derived: sum of 3 quarters · filed 2026-05-07 | $8.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.07M derived: sum of 2 quarters · filed 2026-02-26 | $6.26M derived: sum of 3 quarters · filed 2026-08-06 | $6.83M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.02M derived: sum of 2 quarters · filed 2026-08-06 | $3.59M 10-Q · filed 2025-11-06 | $4.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.75M 10-Q · filed 2026-08-06 | $2.66M derived: sum of 3 quarters · filed 2026-08-06 | $3.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $573.00K 10-Q · filed 2026-05-07 | $1.48M derived: sum of 2 quarters · filed 2026-05-07 | $2.30M derived: sum of 3 quarters · filed 2026-05-07 | $3.12M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $909.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.73M derived: sum of 2 quarters · filed 2026-02-26 | $2.54M derived: sum of 3 quarters · filed 2026-02-26 | $3.52M 10-K · filed 2026-02-26 |
| 2024-09-30 | $819.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.64M derived: sum of 2 quarters · filed 2025-11-06 | $2.61M 10-Q · filed 2025-11-06 | $3.11M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $817.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.79M 10-Q · filed 2025-08-07 | $2.29M derived: sum of 3 quarters · filed 2026-02-26 | $3.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $973.00K 10-Q · filed 2025-05-08 | $1.47M derived: sum of 2 quarters · filed 2026-02-26 | $2.59M derived: sum of 3 quarters · filed 2026-02-26 | $3.92M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $498.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.62M derived: sum of 2 quarters · filed 2026-02-26 | $2.94M derived: sum of 3 quarters · filed 2026-02-26 | $3.47M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.45M derived: sum of 2 quarters · filed 2024-11-12 | $2.97M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $1.85M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $524.00K 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $420.00K 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |